Dalpiciclib isethionate clinical trials
How each study uses dalpiciclib isethionate is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the dalpiciclib isethionate studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- Dalpiciclib Isethionate
- 1
Studies by the year they started
6 studies that test it; most in 2023 (3)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 3 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 2
Jiangsu HengRui Medicine Co., Ltd. (2) · Shandong Suncadia Medicine Co., Ltd. (2) · Tianjin Medical University Cancer Institute and Hospital (1) · Sun Yat-sen University (1)
Often tested with
Tested in the same studies.
HRS-8080 (2) · Adebrelimab (1) · Abiraterone Acetate (1) · Abiraterone (1) · Prednisone (1) · Trastuzumab rezetecan (1) · Camrelizumab (1)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test dalpiciclib isethionate.
- Jun 2027Adebrelimab Combined With Dalpiciclib Isethionate Plus Chemotherapy for Neoadjuvant Treatment of Locally Advanced Head and Neck Squamous Cell CarcinomaPhase 2 · Tianjin Medical University Cancer Institute and Hospital
Studies
Open first, then newest update. How each study uses dalpiciclib isethionate is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Adebrelimab Combined With Dalpiciclib Isethionate Plus Chemotherapy for Neoadjuvant Treatment of Locally Advanced Head and Neck Squamous Cell CarcinomaNot yet recruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07778732Written as Dalpiciclib Isethionate
- A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy.RecruitingPhase 3Shandong Suncadia Medicine Co., Ltd.NCT07354022Written as HRS-8080 Tablet ; Dalpiciclib Isethionate
- Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast CancerRecruitingPhase 1/2Shandong Suncadia Medicine Co., Ltd.NCT06167694Written as HRS-8080; Dalpiciclib Isethionate Tablets
- Dalpiciclib Isethionate Tablets Combined With Abiraterone Acetate Tablets (I) and Prednisone Tablets (AA-P) Versus Placebo Combined With AA-P in Treatment of High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)Not yet recruitingPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT06099990Written as dalpiciclib isethionate tablets; abiraterone acetate tablets; prednisone tablets
- A Phase Ⅰb/Ⅱ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.Not yet recruitingPhase 1/2Jiangsu HengRui Medicine Co., Ltd.NCT05792410Written as SHR-A1811 & Dalpiciclib Isethionate Tablets
- CDK4/6 Inhibitor Plus Camrelizumab for PD-1 Inhibitor Refractory R/M NPCStatus unknownPhase 2Sun Yat-sen UniversityNCT05724355Written as Dalpiciclib Isetionate Tablets, Camrelizumab
Given beside what is tested · 3 — dalpiciclib isethionate is usual care or a partner of the new treatment
- Dalpiciclib Plus Camrelizumab for HCC Patients Who Have Previously Received ICI TreatmentRecruitingPhase 2Sun Yat-sen UniversityNCT07238881Written as Dalpiciclib Isetionate Tablets
- A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid TumorsRecruitingPhase 1/2Risen (Suzhou) Pharma Tech Co., Ltd.NCT06208410Written as Dalpiciclib Isetionate Tablets
- Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02)Active, not recruitingPhase 2Henan Cancer HospitalNCT05328440Written as Dalpiciclib Isethionate Tablets
Codes
What other systems call dalpiciclib isethionate · ClinicalTrials.gg INT014411
- UNII (FDA) 24DCK9FQ92DALPICICLIB ISETHIONATEOne source FDA
- NCI Thesaurus C205439Dalpiciclib IsethionateOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 24DCK9FQ92 | DALPICICLIB ISETHIONATE | One source FDA |
| NCI Thesaurus | C205439 | Dalpiciclib Isethionate | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.